Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a study titled ‘Retrospective Study Evaluating ABRYSVO Vaccine Effectiveness Against Severe Lower Respiratory Tract Infection in Older Adults.’ The study aims to assess the effectiveness of the ABRYSVO vaccine in preventing severe respiratory syncytial virus (RSV) infections in adults aged 60 and older. This research is significant as RSV can lead to severe respiratory issues, especially in older populations.
The intervention being tested is the ABRYSVO vaccine, a biological treatment intended to prevent RSV infections. The vaccine is part of the standard care and is not administered as part of this study.
The study is observational and employs a retrospective case-control design. It uses healthcare data from routine visits, focusing on RSV-related outcomes and all-cause outcomes. The primary purpose is to estimate the vaccine’s effectiveness against RSV-related lower respiratory tract disease requiring hospitalization.
The study started on November 1, 2023, with an estimated completion date in July 2025. These dates are crucial as they indicate the timeline for data collection and analysis, which will inform the vaccine’s effectiveness.
This study update could positively influence Pfizer’s stock performance by reinforcing investor confidence in the company’s vaccine portfolio. It also positions Pfizer competitively in the vaccine market, particularly against other companies developing RSV vaccines.
The study is ongoing, with further details available on the ClinicalTrials portal.